Compare Recursion Pharmaceuticals Inc (RXRX) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs SoundHound AI Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $4.17 (market cap $2.14B), while SoundHound AI Inc trades at $5.47 (market cap $2.45B). The key difference: Recursion Pharmaceuticals Inc and SoundHound AI Inc are close in size by market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and SoundHound AI Inc for 23 Days on average.
| RXRX | SOUN | |
|---|---|---|
Market Cap | $2.14B | $2.45B |
Volume | 30,789,535 | 16,881,989 |
Sector | Health | Technology |
52-Week High | $6.79 | $21.40 |
52-Week Low | $2.84 | $5.52 |
Typical Hold Time | 22 Days | 23 Days |
Enterprise Value | $1.66B | $2.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
SoundHound AI (SOUN) trades at $5.49, down 2.49% today, with bearish technical signals but strong analyst support. The company shows robust revenue growth with 2025 revenue of $168.92M and 2026 projected at $203M, though it remains unprofitable with a -67.45% net margin. Recent developments include expansion in restaurant and banking sectors with voice AI technology, while technical indicators show oversold conditions with RSI at 25-29.
The outlook remains speculative with significant execution risk despite 75% analyst buy ratings and a $9.33 consensus target. Key opportunities include voice AI market expansion and enterprise contract wins, while risks center on persistent losses, high valuation multiples, and competitive pressures in the AI sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
